Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 12/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25213054 | 0.89 | ACVR1 (0.46) | ACVR1PAK4KDM4EMEN1MAPT | |
| SCHEMBL25200579 | 0.81 | ACVR1 (0.57) | ACVR1 | |
| SCHEMBL25195843 | 0.81 | ACVR1 (0.56) | ACVR1PAK4ASIC3KDM4EMEN1 | |
| SCHEMBL25204128 | 0.81 | ACVR1 (0.64) | ACVR1PAK4 | |
| SCHEMBL25520041 | 0.78 | ACVR1 (0.55) | ACVR1PAK4SMN1; SMN2PAK1 | |
| SCHEMBL25520889 | 0.74 | ACVR1 (0.40) | ACVR1PAK4 | |
| SCHEMBL31095453 | 0.72 | ACVR1 (0.61) | ACVR1PAK4KDM4EMEN1MAPT | |
| SCHEMBL20589975 | 0.72 | ACVR1 (0.61) | ACVR1PAK4KDM4EMEN1MAPT | |
| SCHEMBL25519696 | 0.71 | ACVR1 (0.56) | ACVR1 | |
| SCHEMBL29539483 | 0.69 | PAK4 (0.53) | PAK4MEN1KMT2APAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ACVR1 4/4885PAK4 610/4885ASIC3 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.